Antiviral Peptide with Cell-Penetrating Sequence for Filovirus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral diseases, particularly those caused by Filoviridae such as Ebolavirus and Marburgvirus, lack effective preventative and therapeutic agents, and existing antiviral agents may lead to drug resistance, necessitating the development of novel antiviral peptides with different mechanisms of action.
Innovation Solution
A synthetic peptide with a specific amino acid sequence, combined with a cell-penetrating peptide sequence, is designed to suppress viral proliferation, comprising an amino acid sequence represented by SEQ ID NOS:1 to 10, or modified versions thereof, and a CPP sequence, which can be linked directly or via a linker to the N-terminal or C-terminal end, effectively inhibiting viral growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral agents are used, then viral infection can be treated, but drug resistance may develop and treatment options become limited
Solution Approach 1:
The patent changes the fundamental parameters of antiviral agents by transitioning from conventional small-molecule drugs to peptide-based agents with different mechanisms of action. The synthesized peptides have specific amino acid sequences and structures that enable them to interact with viral components in novel ways, thereby maintaining effectiveness while reducing the risk of drug resistance and expanding treatment options.
2Reliability
If naturally occurring antiviral peptides are used, then viral proliferation can be suppressed, but their structural diversity and effectiveness against emerging viruses are limited
Solution Approach 1:
The patent employs segmentation by dividing the antiviral peptide into functional modules: a core peptide sequence (SEQ ID NOS: 1-10) responsible for antiviral activity, and optional cell-penetrating peptide sequences (CPP) that enhance cellular uptake. This modular design allows for systematic variation and optimization of different peptide components to achieve both high efficacy and structural diversity.
Solution Approach 2:
The patent creates universality by designing a core peptide framework that can be combined with multiple different CPP sequences and modification options. This universal core structure maintains consistent antiviral activity while the variable components provide adaptability to different viral targets and delivery requirements, enabling a single platform to address multiple viral infections.
3Reliability
If synthetic peptides with cell-penetrating sequences are designed, then viral proliferation suppression is enhanced, but peptide complexity and manufacturing requirements increase
Solution Approach 1:
The patent applies partial action by incorporating cell-penetrating peptide sequences only when and where needed to enhance viral proliferation suppression, rather than making them a mandatory component of all antiviral peptides. The core peptide structure (SEQ ID NOS: 1-10) provides baseline antiviral activity, while CPP sequences are added selectively to achieve enhanced efficacy in specific applications, thereby balancing complexity with functionality.
Data Source
AI summary
The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues.